Suppr超能文献

蛛网膜下腔出血后脑脊液和血浆中的凝血及纤溶激活

Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage.

作者信息

Ikeda K, Asakura H, Futami K, Yamashita J

机构信息

Department of Neurosurgery, Kanazawa University School of Medicine, Japan.

出版信息

Neurosurgery. 1997 Aug;41(2):344-9; discussion 349-50. doi: 10.1097/00006123-199708000-00002.

Abstract

OBJECTIVE

Intrathecal fibrinolytic therapy has been used as one of the anticerebral vasospasm (VS) preventative therapies in patients with subarachnoid hemorrhage (SAH). However, the changes in coagulation and fibrinolysis in the blood and cerebrospinal fluid (CSF) after SAH remain unknown.

METHODS

Fifty patients with SAH caused by ruptured cerebral aneurysms were studied postoperatively to detect the serial changes of the thrombin-antithrombin III complex, active plasminogen activator inhibitor (PAI)-1, and tissue plasminogen activator (tPA)-PAI complex (tPA-PAI) activities in the plasma and CSF collected from cisternal drainage catheters.

RESULTS

The CSF levels of all parameters and plasma PAI-1 levels were significantly higher in patients with severe SAH than in those with mild SAH. There was no relationship between the CSF and plasma levels of these parameters (except the CSF levels of tPA-PAI) and the initial neurological statuses. The CSF PAI-1 levels increased to greater than 20 ng/ml near the time of the occurrence of cerebral VS, whereas they remained below 20 ng/ml in patients without VS. The CSF tPA-PAI levels showed the highest peak near the time of VS remission. The CSF PAI-1 and tPA-PAI levels were significantly lower in patients with good outcomes than in those with poor outcomes.

CONCLUSION

Both the coagulative and fibrinolytic systems were activated in the CSF and plasma after SAH in correlating to the amount of SAH clot. The intrathecal administration of fibrinolytic agents should be started early after surgery, before CSF PAI-1 levels increase, for patients with severe SAH. Patients with CSF PAI-1 levels greater than 20 ng/ml experienced high incidence of VS and poor outcomes.

摘要

目的

鞘内纤维蛋白溶解疗法已被用作蛛网膜下腔出血(SAH)患者抗脑血管痉挛(VS)的预防性治疗方法之一。然而,SAH后血液和脑脊液(CSF)中凝血和纤维蛋白溶解的变化仍不清楚。

方法

对50例因脑动脉瘤破裂导致SAH的患者进行术后研究,以检测从脑池引流导管收集的血浆和CSF中凝血酶 - 抗凝血酶III复合物、活性纤溶酶原激活物抑制剂(PAI)-1和组织纤溶酶原激活物(tPA)-PAI复合物(tPA-PAI)活性的系列变化。

结果

重度SAH患者的所有参数的CSF水平和血浆PAI-1水平均显著高于轻度SAH患者。这些参数的CSF和血浆水平(tPA-PAI的CSF水平除外)与初始神经状态之间无相关性。在发生脑VS时,CSF PAI-1水平升高至大于20 ng/ml,而无VS的患者其水平保持在20 ng/ml以下。CSF tPA-PAI水平在VS缓解时显示出最高峰值。预后良好的患者CSF PAI-1和tPA-PAI水平显著低于预后不良的患者。

结论

SAH后CSF和血浆中的凝血和纤维蛋白溶解系统均被激活,与SAH血凝块的量相关。对于重度SAH患者,应在术后早期、CSF PAI-1水平升高之前开始鞘内注射纤维蛋白溶解剂。CSF PAI-1水平大于20 ng/ml的患者发生VS的发生率高且预后不良。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验